Articles - GLP1 drugs changing weight loss and Life & Health insurance


Weight-loss injectables like Wegovy or Ozempic are gaining popularity amid an escalating global obesity crisis. Since 1975, worldwide obesity rates have nearly tripled, with projections indicating that over half of the global population will be overweight or obese by 2035. John Schoonbee, Global Chief Medical Officer, and Adam Strange, Life & Health R&D Manager, elaborate on the impact of GLP-1 drugs on weight loss, metabolic health and insurance. These medications influence risk factors such as insulin resistance, cardiovascular disease, and cancer. Additionally, they discuss the implications of these drugs on Life & Health insurance, including life, critical illness, and disability income, as well as future underwriting risk assessments.

 

Back to Index


Similar News to this Story

The value of a modelling framework for insurers
At this year’s GIRO Conference in Liverpool, my colleagues at LCP gave several excellent talks on a range of topics – from claims analytics to reser
Collaboration required for the vision for private markets
Whether it’s a defined benefit scheme, a defined contribution scheme or a collective defined contribution scheme, trustees and providers are likely to
Coping with extreme climate and geopolitical uncertainty
Thriving in the face of hyper-volatility means building financial resilience using a combination of quantitative analytics and qualitative ‘storytelli

Site Search

Exact   Any  

Latest Actuarial Jobs

Actuarial Login

Email
Password
 Jobseeker    Client
Reminder Logon

APA Sponsors

Actuarial Jobs & News Feeds

Jobs RSS News RSS

WikiActuary

Be the first to contribute to our definitive actuarial reference forum. Built by actuaries for actuaries.